Intensity Therapeutics Clears Nasdaq $1.00 Minimum Bid Requirement With 10-Day Streak
Intensity Therapeutics' stock closed at or above $1.00 for 10 consecutive business days from February 19 to March 4, 2026, meeting Nasdaq Listing Rule 5550(a)(2) and resolving its compliance issue. This secures Nasdaq listing as Intensity advances Phase 3 sarcoma and Phase 2 triple-negative breast cancer trials of INT230-6 therapy.
1. Regains Nasdaq Listing Compliance
On March 6, Intensity Therapeutics received formal notice that it met the Nasdaq minimum bid price requirement after its common stock closed at or above $1.00 per share for 10 consecutive business days from February 19 through March 4, 2026. Nasdaq has closed the compliance matter, securing the company’s continued listing status and avoiding the risk of delisting.
2. Clinical Pipeline Progress
Intensity’s lead asset, INT230-6, is progressing through a Phase 3 soft tissue sarcoma trial (INVINCIBLE-3) and a Phase 2 pre-surgical triple-negative breast cancer study (INVINCIBLE-4). The intratumoral therapy combines cisplatin, vinblastine sulfate and a diffusion enhancer to kill tumors and trigger immune responses without systemic immunosuppression.